Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is 10.80% higher on its value in year-to-date trading and has touched a low of $99.06 and a high of $148.06 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The JAZZ stock was last observed hovering at around $140.23 in the last trading session, with the day’s loss setting it -3.78%.
Currently trading at $136.45, the stock is 0.84% and 6.76% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.25 million and changing -2.70% at the moment leaves the stock 17.57% off its SMA200. JAZZ registered 16.10% gain for a year compared to 6-month gain of 24.82%.
The stock witnessed a 12.18% loss in the last 1 month and extending the period to 3 months gives it a 12.23%, and is -4.76% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.14% over the week and 3.44% over the month.
Jazz Pharmaceuticals plc (JAZZ) has around 2800 employees, a market worth around $8.29B and $4.07B in sales. Current P/E ratio is 15.60 and Fwd P/E is 5.89. Profit margin for the company is 13.77%. Distance from 52-week low is 37.74% and -7.84% from its 52-week high. The company has generated returns on investments over the last 12 months (5.48%).
with sales reaching $984.56M over the same period.The EPS is expected to grow by 10.99% this year, but quarterly earnings will post 5.39% year-over-year. Quarterly sales are estimated to grow 9.15% in year-over-year returns.
The shares outstanding are 60.63M, and float is at 58.06M with Short Float at 7.80%.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 6.32 million shares valued at $674.82 million. The investor’s holdings represent 10.1103 of the JAZZ Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.15 million shares valued at $655.94 million to account for 9.8274 of the shares outstanding. The other top investors are LSV ASSET MANAGEMENT which holds 2.48 million shares representing 3.9448 and valued at over $264.75 million, while STATE STREET CORP holds 3.2258 of the shares totaling 2.02 million with a market value of $215.31 million.
Jazz Pharmaceuticals plc (JAZZ) Insider Activity
The most recent transaction is an insider sale by Carr Patricia, the company’s SVP, Chief Accounting Officer. SEC filings show that Carr Patricia sold 4,813 shares of the company’s common stock on Feb 27 ’25 at a price of $144.42 per share for a total of $0.7 million. Following the sale, the insider now owns 8237.0 shares.
Jazz Pharmaceuticals plc disclosed in a document filed with the SEC on Feb 28 ’25 that Carr Patricia (SVP, Chief Accounting Officer) sold a total of 773 shares of the company’s common stock. The trade occurred on Feb 28 ’25 and was made at $143.29 per share for $0.11 million. Following the transaction, the insider now directly holds 9485.0 shares of the JAZZ stock.
Still, SEC filings show that on Feb 27 ’25, Patil Neena M (EVP & Chief Legal Officer) disposed off 3,800 shares at an average price of $144.87 for $0.55 million. The insider now directly holds 33,318 shares of Jazz Pharmaceuticals plc (JAZZ).
